<DOC>
	<DOCNO>NCT00375674</DOCNO>
	<brief_summary>To compare disease free survival time safety sunitinib placebo adjuvant treatment patient high risk recurrent kidney cancer surgery .</brief_summary>
	<brief_title>A Clinical Trial Comparing Efficacy And Safety Of Sunitinib Versus Placebo For TheTreatment Of Patients At High Risk Of Recurrent Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Sunitinib</mesh_term>
	<criteria>High risk renal cancer per modify UISS criterion Eastern Cooperative Oncology Group ( ECOG ) 02 predominant clear cell histology No prior anticancer treatment Kidney tumor remove No evidence macroscopic disease follow surgery Histologically undifferentiated carcinoma collect duct carcinoma , lymphoma , sarcoma subject metastatic renal site . Diagnosis second malignancy within last 5 year , except basal cell carcinoma , squamous cell skin cancer , situ carcinoma cervix uteri adequately treat evidence recurrent disease 12 month know HIV Hepatitis severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation study drug administration</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>